Retrospective Study of Romiplostim for Platelet Engraftment After Allo-HSCT

Completed

Conditions studied: Thrombocytopenia

In brief

This is a retrospective observational study evaluating the efficacy and safety of romiplostim for promoting platelet engraftment in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Tongji Hospital Afﬁliated to Tongji Medical College of Huazhong University of Science and Technology between January 2025 to May 2026. Medical records were reviewed to collect data on platelet recovery time, transfusion requirements, and adverse events. The primary endpoint was time to platelet engraftment. Secondary endpoints included platelet recovery kinetics, transfusion requirements, transplant-related complications, and safety outcomes.No interventions were assigned as part of this study.

Key facts

Study ID: NCT07747246
Run by: Tongji Hospital
People needed: 103
Starts: 2025-01-01
Expected to finish: 2026-07-15
Last updated by the study team: 2026-08-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients diagnosed with AA, AL, MDS, PMF, or other hematologic diseases according to internationally accepted diagnostic criteria
Patients who underwent allo-HSCT during the study period
Patients with complete clinical characteristics, transplantation records, and follow-up data

You may not qualify if…

Primary graft failure;
Death before hematopoietic engraftment
Missing key clinical data;(4) Use of thrombopoietin receptor agonists other than romiplostim

Where it is running

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.